Five veteran clinicians have been recognized for their lasting impact on the field of pediatric cardiology. 

Rishi Wadhera, MD, MPP, MPhil, a cardiologist who also specializes in healthcare policy, spoke to Cardiovascular Business about the good, the bad and the unknown when it comes to private equity's role in cardiology.

Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.

Mario Gaudino, MD, PhD, spoke to Cardiovascular Business about minimally invasive procedures, the growing interest in clinical trials and other key trends in the world of cardiac surgery.

PPMI after aortic valve surgery is known to increase certain risks for patients, but its impact after mitral valve procedures is unclear. A team of researchers aimed to learn more, tracking data from more than 4,500 patients.

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

"The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.